Beijing Hotgen Biotech Co., Ltd. (688068.SS)
CNY 121.5
(5.55%)
CNY 121.5
(5.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 85.04 Million CNY | -93.47% |
| 2022 | 1.19 Billion CNY | -50.09% |
| 2021 | 2.65 Billion CNY | 1649.28% |
| 2020 | 157.01 Million CNY | 153.93% |
| 2019 | 64.38 Million CNY | -14.36% |
| 2018 | 78.54 Million CNY | 58.86% |
| 2017 | 50.63 Million CNY | 4.97% |
| 2016 | 41.76 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 17.95 Million CNY | 659.29% |
| 2024 Q2 | -5.32 Million CNY | 92.51% |
| 2024 Q1 | -30.4 Million CNY | -94.09% |
| 2023 Q1 | 35.7 Million CNY | -55.36% |
| 2023 FY | - CNY | -93.47% |
| 2023 Q4 | -3.48 Million CNY | 94.94% |
| 2023 Q3 | -68.88 Million CNY | -221.94% |
| 2023 Q2 | 56.48 Million CNY | 58.2% |
| 2022 Q1 | 705.11 Million CNY | 45.82% |
| 2022 Q2 | 222.36 Million CNY | -68.46% |
| 2022 Q4 | 79.99 Million CNY | -68.66% |
| 2022 Q3 | 255.26 Million CNY | 14.79% |
| 2022 FY | - CNY | -50.09% |
| 2021 Q3 | 212.86 Million CNY | -83.44% |
| 2021 Q2 | 1.28 Billion CNY | 81.71% |
| 2021 Q1 | 707.24 Million CNY | 462.1% |
| 2021 FY | - CNY | 1649.28% |
| 2021 Q4 | 483.53 Million CNY | 127.16% |
| 2020 Q4 | 125.82 Million CNY | 8982.33% |
| 2020 FY | - CNY | 153.93% |
| 2020 Q1 | -1 Million CNY | -104.13% |
| 2020 Q3 | -1.41 Million CNY | -130.49% |
| 2020 Q2 | 4.64 Million CNY | 562.37% |
| 2019 FY | - CNY | -14.36% |
| 2019 Q3 | 2.7 Million CNY | -82.66% |
| 2019 Q2 | 15.6 Million CNY | 796.46% |
| 2019 Q1 | -2.24 Million CNY | -106.39% |
| 2019 Q4 | 24.33 Million CNY | 799.04% |
| 2018 Q3 | 4.6 Million CNY | 0.0% |
| 2018 FY | - CNY | 58.86% |
| 2018 Q4 | 35.05 Million CNY | 660.82% |
| 2018 Q1 | 4.22 Million CNY | 0.0% |
| 2017 FY | - CNY | 4.97% |
| 2016 FY | - CNY | 0.0% |